Cellectis (CLLS) Cash & Equivalents (2013 - 2026)

Cellectis' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $34.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 72.7% year-over-year to $34.8 million in Q1 2026; TTM through Mar 2026 was $34.8 million, a 72.7% decrease from a year earlier, with the FY2025 full-year figure at $61.5 million, down 57.05% from the prior year.
• Cash & Equivalents declined to $34.8 million in Q1 2026 per CLLS's latest filing, from $61.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $159.1 million in Q3 2024 and bottomed at $34.8 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $97.6 million (2022), against an average of $103.4 million.
• Across the five-year window, Cash & Equivalents surged 136.18% in 2024 and slumped 72.7% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $93.2 million in 2022, then soared by 46.66% to $136.7 million in 2023, then gained by 4.79% to $143.3 million in 2024, then plunged by 57.05% to $61.5 million in 2025, then slumped by 43.38% to $34.8 million in 2026.
• Per Business Quant, the three latest CLLS Cash & Equivalents figures stand at $34.8 million (Q1 2026), $61.5 million (Q4 2025), and $52.2 million (Q3 2025).